First human trial aims to starve lung cancer cells
NCT ID NCT03467360
Summary
This early-stage trial is testing whether adding an existing drug called acetazolamide to standard radiation and chemotherapy can better control small cell lung cancer. The drug may work by targeting the cancer's energy supply and making the tumor environment less acidic, which could help the immune system. The study will first determine the safest dose of this combination for 27 patients with either limited or extensive stage disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Antoine Lacassagne
RECRUITINGNice, 06189, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier Princesse grace
TERMINATEDMonte Carlo, Monaco
Conditions
Explore the condition pages connected to this study.